{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-037928","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.605311+00:00","generated_at":"2026-06-15T07:15:45.384747+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cadrenal Therapeutics reports Q1 2023 cash of $4M, Fast Track for tecarfarin","bullets":["FDA granted Fast Track designation for tecarfarin in ESRD/AFib patients in Jan 2023.","Completed IPO raising $7.0M gross proceeds; cash at March 31, 2023 was $4.0M.","Q1 2023 operating expenses (ex-non-cash) were $913,653; cash expected to fund through Q2 2024.","Plans Phase 3 ACTOR-AF trial (492 patients) as pivotal step before NDA submission.","Market opportunity for tecarfarin estimated up to $1B annually if FDA approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-037928","json":"https://secwatch.observer/filing/0001213900-23-037928.json","markdown":"https://secwatch.observer/filing/0001213900-23-037928.md","text":"https://secwatch.observer/filing/0001213900-23-037928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023037928/0001213900-23-037928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023037928/ea178256-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:15:45.384747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f87e81cd2905f25e14ee379b10152e1c2d05d9a9","claim":"Cadrenal Therapeutics, Inc. reported preliminary financial results for the fiscal quarter ended March 31, 2023.","evidence_excerpt":"On May 10, 2023, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390023037928/0001213900-23-037928-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}